Management of prostate cancer. Part 1: chemoprevention

References

• Hampton T. Clinical trials point to complexities of chemoprevention for cancer. JAMA294, 29–31 (2005).
   Google Scholar
• Kismet K, Akay MT, Abbasoglu O, Ercan A. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect. Prev. 28, 127–142 (2004).
   PubMedGoogle Scholar
• Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol. 150, 379–385 (1993).
   PubMed Web of Science ®Google Scholar
• Breslow N, Chan CW, Dhom G et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int. J. Cancer 20, 680–688 (1977).
   PubMed Web of Science ®Google Scholar
• Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA, Correa P. Geographic pathology of latent prostatic carcinoma. Int. J. Cancer 29, 611–616 (1982).
   PubMed Web of Science ®Google Scholar
• Deutsch E, Maggiorella L, Eschwege P, Bourhis J, Soria JC, Abdulkarim B. Environmental, genetic, and molecular features of prostate cancer. Lancet Oncol. 5, 303–313 (2004).
   PubMed Web of Science ®Google Scholar
• Fleshner N, Al Azab R. Prostate cancer: chemoprevention update 2005. Cancer J. Urol. 12 (Suppl. 2), 2–4 (2005).
   Google Scholar
• Fujimoto N, Chang C, Nomura M, Matsumoto T. Can we prevent prostate cancer? Rationale and current status of prostate cancer chemoprevention. Urol. Int. 74, 289–297 (2005).
   PubMed Web of Science ®Google Scholar
• Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343, 78–85 (2000).
   PubMed Web of Science ®Google Scholar
• Thompson IM, Coltman CA Jr, Crowley J. Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. Prostate 33, 217–221 (1997).
   PubMed Web of Science ®Google Scholar
• Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215–224 (2003).
   PubMed Web of Science ®Google Scholar
• Civantos F, Soloway MS, Pinto JE. Histopathological effects of androgen deprivation in prostatic cancer. Semin. Urol. Oncol. 14, 22–31 (1996).
   PubMedGoogle Scholar
• Bostwick DG. Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation. Anat. Pathol. 3, 1–16 (1998).
   PubMedGoogle Scholar
• Kirby RS, Fitzpatrick JM. How should we advise patients about the chemoprevention of prostate cancer? BJU Int. 96, 231–232 (2005).
   Google Scholar
• Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. Curr. Opin. Urol. 14, 143–149 (2004).
   PubMed Web of Science ®Google Scholar
• Shibata Y, Ito K, Suzuki K, Nakano K et al. Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 42, 45–55 (2000).
   PubMedGoogle Scholar
• Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J. Natl Cancer Inst. 76, 45–48 (1986).
   PubMed Web of Science ®Google Scholar
• Mobbs BG, Johnson IE, Connolly JG, Thompson J. Concentration and cellular distribution of androgen receptor in human prostatic neoplasia: can estrogen treatment increase androgen receptor content? J. Steroid Biochem. 19, 1279–1290 (1983).
   PubMedGoogle Scholar
• Moore RJ, Gazak JM, Wilson JD. Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17 β-estradiol. J. Clin. Invest. 63, 351–357 (1979).
   PubMed Web of Science ®Google Scholar
• Blanchere M, Berthaut I, Portois MC, Mestayer C, Mowszowicz I. Hormonal regulation of the androgen receptor expression in human prostatic cells in culture. J. Steroid Biochem. Mol. Biol. 66, 319–326 (1998).
   PubMed Web of Science ®Google Scholar
• Leav I, Ho SM, Ofner P, Merk FB, Kwan PW, Damassa D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J. Natl Cancer Inst. 80, 1045–1053 (1988).
   PubMedGoogle Scholar
• Leav I, Merk FB, Kwan PW, Ho SM. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 15, 23–40 (1989).
   PubMed Web of Science ®Google Scholar
• Waters DJ, Bostwick DG. The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Anticancer Res. 17, 1467–1470 (1997).
   PubMed Web of Science ®Google Scholar
• Price KR, Fenwick GR. Naturally occurring oestrogens in foods – a review. Food Addit. Contam. 2, 73–106 (1985).
   PubMed Web of Science ®Google Scholar
• Wang S, DeGroff VL, Clinton SK. Tomato and soy polyphenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J. Nutr. 133, 2367–2376 (2003).
   PubMed Web of Science ®Google Scholar
• Denis L, Morton MS, Griffiths K. Diet and its preventive role in prostatic disease. Eur. Urol. 35, 377–387 (1999).
   PubMed Web of Science ®Google Scholar
• Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 62, 1370–1376 (2002).
   PubMed Web of Science ®Google Scholar
• Steiner M, Pound CR, Gingrich, JR, et al. Acapodene (GTx-006) reduces high grade prostatic intraepithelial neoplasia (HGPIN) in a Phase II clinical trial. 38th Annual Meeting of American Society of Clinical Oncology: 18–21 (2002) (Abstract 719).
   Google Scholar
• Kim IY, Kim BC, Seong do H et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res. 62, 5365–5369 (2002).
   PubMed Web of Science ®Google Scholar
• Heston WD, Kadmon D, Lazan DW, Fair WR. Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor α-difluoromethylornithine. Prostate 3, 383–389 (1982).
   PubMed Web of Science ®Google Scholar
• Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, α-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res. 51, 4528–4534 (1991).
   PubMed Web of Science ®Google Scholar
• Ratko TA, Detrisac CJ, Rao KV, Thomas CF, Kelloff GJ, Moon RC. Interspecies analysis of the chemopreventive efficacy of dietary alpha-difluoromethylornithine. Anticancer Res. 10, 67–72 (1990).
   PubMed Web of Science ®Google Scholar
• Rao KV, Johnson WD, Bosland MC et al. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res. 59, 3084–3089 (1999).
   PubMed Web of Science ®Google Scholar
• Peehl DM, Wong ST, Stamey TA. Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate 23, 69–78 (1993).
   PubMed Web of Science ®Google Scholar
• Samid D, Shack S, Myers CE. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest. 91, 2288–2295 (1993).
   PubMed Web of Science ®Google Scholar
• Carducci MA, Nelson JB, Chan-Tack KM et al. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res. 2, 379–387 (1996).
   Google Scholar
• Rodriguez C, McCullough ML, Mondul AM et al. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol. Biomarkers Prev. 12, 597–603 (2003).
   PubMed Web of Science ®Google Scholar
• Peehl DM, Krishnan AV, Feldman D. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J. Nutr. 133, 2461S–2469S (2003).
   Google Scholar
• Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D. Regulation of target gene expression. J. Cell Biochem. 88, 363–371 (2003).
   PubMed Web of Science ®Google Scholar
• Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J. Urol. 172, S6–S12 (2004).
   Web of Science ®Google Scholar
• Day NE, Bingham SA. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl Cancer Inst. 86, 1645–1648 (1994).
   PubMedGoogle Scholar
• Li JY, Taylor PR, Li B, Dawsey S et al. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J. Natl Cancer Inst. 85, 1492–1498 (1993).
   PubMed Web of Science ®Google Scholar
• Webber MM, Perez-Ripoll EA, James GT. Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem. Biophys. Res. Commun. 130, 603–609 (1985).
   PubMed Web of Science ®Google Scholar
• Nakamura A, Shirai T, Takahashi S, Ogawa K, Hirose M, Ito N. Lack of modification by naturally occurring antioxidants of 3,2′-dimethyl-4-aminobiphenyl-initiated rat prostate carcinogenesis. Cancer Lett. 58, 241–246 (1991).
   PubMed Web of Science ®Google Scholar
• Venkateswaran V, Klotz LH, Fleshner NE. Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res. 62, 2540–2545 (2002).
   PubMedGoogle Scholar
• Zhao H, Whitfield ML, Xu T, Botstein D, Brooks JD. Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Mol. Biol. Cell. 15, 506–519 (2004).
   PubMed Web of Science ®Google Scholar
• Vogt TM, Ziegler RG, Graubard BI et al. Serum selenium and risk of prostate cancer in U.S. blacks and whites. Int. J. Cancer 103, 664–670 (2003).
   PubMed Web of Science ®Google Scholar
• Li H, Stampfer MJ, Giovannucci EL et al. A prospective study of plasma selenium levels and prostate cancer risk. J. Natl Cancer Inst. 96, 696–703 (2004).
   PubMedGoogle Scholar
• Yoshizawa K, Willett WC, Morris SJ et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J. Natl Cancer Inst. 90, 1219–1224 (1998).
   PubMed Web of Science ®Google Scholar
• Clark LC, Combs GF Jr, Turnbull BW et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276, 1957–1963 (1996).
   PubMed Web of Science ®Google Scholar
• Traber MG, Packer L. Vitamin E: beyond antioxidant function. Am. J. Clin. Nutr. 62, 1501S–1509S (1995).
   PubMed Web of Science ®Google Scholar
• Hsing AW, Comstock GW, Abbey H, Polk BF. Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer. J. Natl Cancer Inst. 82, 941–946 (1990).
   PubMed Web of Science ®Google Scholar
• Heinonen OP, Albanes D, Virtamo J et al. Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J. Natl Cancer Inst. 90, 440–446 (1998).
   PubMed Web of Science ®Google Scholar
• Mellon JK. Chemoprevention of prostate cancer comes of age. BJU Int. 93, 459–460 (2004).
   Google Scholar
• Goodman GE, Schaffer S, Omenn GS, Chen C, King I. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from β-carotene and retinol efficacy trial. Cancer Epidemiol. Biomarkers Prev. 12, 518–526 (2003).
   PubMed Web of Science ®Google Scholar
• Klein EA, Lippman SM, Thompson IM et al. The selenium and vitamin E cancer prevention trial. World J. Urol. 21, 21–27 (2003).
   Google Scholar
• Kim HS, Bowen P, Chen L, Duncan C, Ghosh L, Sharifi R, Christov K. Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. Nutr. Cancer. 47, 40–47 (2003).
   PubMed Web of Science ®Google Scholar
• Heber D, Lu QY. Overview of mechanisms of action of lycopene. Exp. Biol. Med. (Maywood) 227, 920–923 (2002).
   PubMed Web of Science ®Google Scholar
• Aust O, Ale-Agha N, Zhang L, Wollersen H, Sies H, Stahl W. Lycopene oxidation product enhances gap junctional communication. Food Chem. Toxicol. 41, 1399–1407 (2003).
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J. Natl Cancer Inst. 87, 1767–1776 (1995).
   PubMed Web of Science ®Google Scholar
• Adhami VM, Ahmad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J. Nutr. 133, 2417S–2424S (2003).
   PubMed Web of Science ®Google Scholar
• Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, Mukhtar H. Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 22, 4851–4859 (2003).
   PubMed Web of Science ®Google Scholar
• Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, Heston WD. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J. Natl Cancer Inst. 87, 1456–1462 (1995).
   PubMed Web of Science ®Google Scholar
• Pollard M, Luckert PH. Promotional effects of testosterone and high fat diet on the development of autochthonous prostate cancer in rats. Cancer Lett. 32, 223–227 (1986).
   PubMedGoogle Scholar
• Pour PM, Groot K, Kazakoff K, Anderson K, Schally AV. Effects of high-fat diet on the patterns of prostatic cancer induced in rats by N-nitrosobis(2-oxopropyl)amine and testosterone. Cancer Res. 51, 4757–4761 (1991).
   Google Scholar
• Clinton SK, Palmer SS, Spriggs CE, Visek WJ. Growth of Dunning transplantable prostate adenocarcinomas in rats fed diets with various fat contents. J. Nutr. 118, 908–914 (1988).
   Google Scholar
• Carroll KK, Khor HT. Dietary fat in relation to tumorigenesis. Prog. Biochem. Pharmacol. 10, 308–353 (1975).
   PubMedGoogle Scholar
• Bairati I, Meyer F, Fradet Y, Moore L. Dietary fat and advanced prostate cancer. J. Urol. 159, 1271–1275 (1998).
   PubMed Web of Science ®Google Scholar
• Schuurman AG, van den Brandt PA, Dorant E, Brants HA, Goldbohm RA. Association of energy and fat intake with prostate carcinoma risk: results from The Netherlands Cohort Study. Cancer 86, 1019–1027 (1999).
   PubMed Web of Science ®Google Scholar
• Pandalai PK, Pilat MJ, Yamazaki K, Naik H, Pienta KJ. The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res. 16, 815–820 (1996).
   Google Scholar
• Aronson WJ, Glaspy JA, Reddy ST, Reese D, Heber D, Bagga D. Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology 58, 283–288 (2001).
   PubMed Web of Science ®Google Scholar
• Mazhar D, Waxman J. Diet and prostate cancer. BJU Int. 93, 919–922 (2004).
   Google Scholar
• Gann PH, Hennekens CH, Sacks FM, Grodstein F, Giovannucci EL, Stampfer MJ. Prospective study of plasma fatty acids and risk of prostate cancer. J. Natl Cancer Inst. 86, 281–286 (1994).
   PubMedGoogle Scholar
• Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J. Natl Cancer Inst. 91, 512–523 (1999).
   PubMedGoogle Scholar
• Rubenstein M, Shaw MW, McKiel CF, Ray PS, Guinan PD. Immunoregulatory markers in rats carrying Dunning R3327 H, G, or MAT-LyLu prostatic adenocarcinoma variants. Cancer Res. 47, 178–182 (1987).
   PubMed Web of Science ®Google Scholar
• Shaw MW, Ablin RJ, Ray P, Rubenstein M, Guinan PD, McKiel CF. Immunobiology of the Dunning R-3327 rat prostate adenocarcinoma sublines: plasma and tumor effusion prostaglandins. Am. J. Reprod. Immunol. Microbiol. 8, 77–79 (1985).
   Google Scholar
• Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42, 73–78 (2000).
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Sano H, Masuda C et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer. 89, 589–596 (2000).
   Google Scholar
• Lee LM, Pan CC, Cheng CJ, Chi CW, Liu TY. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res. 21, 1291–1294 (2001).
   PubMed Web of Science ®Google Scholar
• Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol. Res. 29, 23–28 (2001).
   PubMedGoogle Scholar
• Madaan S, Abel PD, Chaudhary KS et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int. 86, 736–741 (2000).
   PubMed Web of Science ®Google Scholar
• Zha S, Gage WR, Sauvageot J et al. Cyclooxygenase-2 is upregulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 61, 8617–8623 (2001).
   PubMed Web of Science ®Google Scholar
• Shappell SB, Manning S, Boeglin WE et al. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 3, 287–303 (2001).
   PubMed Web of Science ®Google Scholar
• Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control. 13, 427–434 (2002).
   PubMed Web of Science ®Google Scholar
• Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int. J. Cancer 106, 409–415 (2003).
   PubMed Web of Science ®Google Scholar
• Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin. Proc. 77, 219–225 (2002).
   PubMed Web of Science ®Google Scholar
• Leitzmann MF, Stampfer MJ, Ma J et al. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 11, 1108–1111 (2002).
   PubMed Web of Science ®Google Scholar
• Irani J, Ravery V, Pariente JL et al. Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J. Urol. 168, 1985–1988 (2002).
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Gonzalez-Perez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 13, 649–653 (2004).
   Google Scholar
• Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case–control study. Oncol. Rep. 7, 169–170 (2000).
   PubMed Web of Science ®Google Scholar
• Platz EA, Rohrmann S, Pearson JD et al. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol. Biomarkers Prev. 14, 390–396 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobs EJ, Rodriguez C, Mondul AM et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J. Natl Cancer Inst. 97, 975–980 (2005).
   PubMed Web of Science ®Google Scholar
• Costello LC, Feng P, Milon B, Tan M, Franklin RB. Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis. 7, 111–117 (2004).
   PubMed Web of Science ®Google Scholar
• Schoonen WM, Salinas CA, Kiemeney LA, Stanford JL. Alcohol consumption and risk of prostate cancer in middle-aged men. Int. J. Cancer 113, 133–140 (2005).
   PubMed Web of Science ®Google Scholar
• Uzzo RG, Brown JG, Horwitz EM et al. Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer. BJU Int. 93, 955–960 (2004).
   Google Scholar